Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab + GEMOX in KRAS/BRAF Wild-Type Biliary Tract Cancer
NCT01308840Phase 2Completed
- Sponsor
- University of Rochester
- Start
- Dec 2010
- Primary completion
- Jan 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of panitumumab in biliary tract cancer (BTC), gallbladder cancer, sponsored by University of Rochester. Started Dec 2010; status: completed.
02
Drugs
panitumumab
03
Conditions
biliary tract cancer (BTC)gallbladder cancer
Beyond the preview
Go deeper on NCT01308840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01308840.